Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antipsychotic Not Certain Savior For Forest

This article was originally published in The Pink Sheet Daily

Executive Summary

Cariprazine shows potential in top-line Phase II, as milnacipran PDUFA date – and firm’s patent cliff – grow near.

You may also be interested in...



Forest Ready To File Antipsychotic Cariprazine With Bipolar Mania Results

Success in a Phase III trial in schizophrenia, set to report in Q1 2012, would mean a double filing in mid-2012.

Forest Ready To File Antipsychotic Cariprazine With Bipolar Mania Results

Success in a Phase III trial in schizophrenia, set to report in Q1 2012, would mean a double filing in mid-2012.

Forest/Almirall’s Aclidinium Disappoints In Phase III COPD Trial

Bronchodilatory effect of aclidinium was statistically significant compared to placebo, but lower than seen in previous studies.

Related Content

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel